Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
7 Cards in this Set
- Front
- Back
|
Pramipexole
|
Direct Acting dopaminergic agent(park)
Non-ergot almost entirely renal excretion S/E- hypotension, dyskinesias, hallucinations |
|
|
Apomorphine
|
Direct acting dopaminergic agent(P)
New non-ergot- sub-q Indicated only for immobility induced by acute "off" episodes of PD Effects w/in 10-20 min, lasts 1 hr Nor more than 3 doses/day S/E- quite common: injection site reactions, hallucinations, yawning, drowsiness, dyskinesias, N/V, penile erection |
|
|
Rotigotine (Neupro)
|
Brand new non-ergot DA-ergic agent (PD)
administered 1/day as transdermal patch |
|
|
Entacapone
|
COMT inhibitor (PD)
-used only in combination w/ levodopa -prevents peripheral destruction of l-dopa by COMT -preferred to tolcapone due to possibility of serious hepatotoxicity of tolcapone S/E- mostly attributable to higher peripheral levels of l-dopa. N?V, hypotension, sleep disturbances, hallucinations, dyskinesias |
|
|
Selegiline
|
MAO-B inhibitor (PD)
-usually 2nd or 3rd line agent due to modest effects -side effects partly produced by increasing CNS levels of dopamine-may be reduced by l-dopa dose reduction -S/E of CNS stimulation contributed to by amphetamine-like metabolites |
|
|
Rasagiline
|
MAO-B inhibitor
-very new anti-Parkinson agent -indicated alone or in combination w/ levodopa -specific anti-Parkinson mechanism of action is not known -liver metabolized -fairly well tolerated-not metabolized to amphetamine-like substances -no comparisons w/ selegiline |
|
|
Amantadine
|
DA release (PD)
-originally develped as antiviral -increases release of DA from surviving neurons in striatu, -may also block DA reuptake -rapid onset of benefits, but often short-lived S/E- CNS- confusion, anxiety, somnolence, sleep disturbances, HA, especially in elderly or renally impaired -antimuscarinic effects |
